Skip to main content

Advertisement

SpringerLink
Log in

Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background

An association between adrenergic alpha-1 receptor antagonists and delirium has been suggested, but the details are unclear.

Aim

This study investigated the association between adrenergic alpha-1 receptor antagonists and delirium in patients with benign prostatic hyperplasia using the Japanese Adverse Drug Event Report database.

Method

First, disproportionality analysis compared the frequency of delirium in the adrenergic alpha-1 receptor antagonists silodosin, tamsulosin, and naftopidil. Next, multivariate logistic analysis was performed to examine the association between delirium and adrenergic alpha-1 receptor antagonists where disproportionality was detected.

Results

A disproportionality in delirium was observed in patients receiving tamsulosin (reporting odds ratio [ROR] 1.85, 95% confidence interval [CI] 1.38–2.44, P < 0.01) compared with those who did not, and also in patients receiving naftopidil (ROR 2.23, 95% CI 1.45–3.28, P < 0.01) compared with those who did not. Multivariate logistic analysis revealed that in addition to previously reported risk factors for delirium, delirium in patients receiving tamsulosin was significantly increased with concomitant use of anticholinergics (odds ratio 2.73, 95% CI 1.41–5.29, P < 0.01) and delirium in patients receiving naftopidil was significantly increased with concomitant use of beta3-adrenergic receptor agonists (odds ratio 4.19, 95% CI 1.66–10.6, P < 0.01).

Conclusion

Anticholinergics or beta3-adrenergic receptor agonists to treat overactive bladder in patients receiving tamsulosin and naftopidil was strongly associated with delirium. Confirming the medical history and concomitant medications of patients receiving tamsulosin or naftopidil may contribute to preventing delirium in patients with benign prostatic hyperplasia and to improving their outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Francis J, Kapoor WN. Delirium in hospitalized elderly. J Gen Intern Med. 1990;5:65–79.

    Article  CAS  PubMed  Google Scholar 

  2. Gibb K, Seeley A, Quinn T, et al. The consistent burden in published estimates of delirium occurrence in medical inpatients over four decades: a systematic review and meta-analysis study. Age Ageing. 2020;49:352–60.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Maldonado JR. Neuropathogenesis of delirium: review of current etiologic theories and common pathways. Am J Geriatr Psychiatry. 2013;21:1190–222.

    Article  PubMed  Google Scholar 

  4. Inouye SK, Westendorp RGJ, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911–22.

    Article  PubMed  Google Scholar 

  5. Thomas RI, Cameron DJ, Fahs MC. A prospective study of delirium and prolonged hospital stay. Exploratory study. Arch Gen Psychiatry. 1988;45:937–40.

    Article  CAS  PubMed  Google Scholar 

  6. Dasgupta M, Brymer C. Prognosis of delirium in hospitalized elderly: worse than we thought. Int J Geriatr Psychiatry. 2014;29:497–505.

    Article  PubMed  Google Scholar 

  7. Salluh JIF, Wang H, Schneider EB, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ. 2015;350:h2538.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Buss MK, Vanderwerker LC, Inouye SK, et al. Associations between caregiver-perceived delirium in patients with cancer and generalized anxiety in their caregivers. J Palliat Med. 2007;10:1083–92.

    Article  PubMed  Google Scholar 

  9. Shankar KN, Hirschman KB, Hanlon AL, et al. Burden in caregivers of cognitively impaired elderly adults at time of hospitalization: a cross-sectional analysis. J Am Geriatr Soc. 2014;62:276–84.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Inouye SK. The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients. Am J Med. 1994;97:278–88.

    Article  CAS  PubMed  Google Scholar 

  11. Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15:15–28.

    Article  CAS  PubMed  Google Scholar 

  12. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301:489–99.

    Article  CAS  PubMed  Google Scholar 

  13. Clegg A, Young JB. Which medications to avoid in people at risk of delirium: a systematic review. Age Ageing. 2011;40:23–9.

    Article  PubMed  Google Scholar 

  14. Egberts A, van der Craats ST, van Wijk MD, et al. Anticholinergic drug exposure is associated with delirium and postdischarge institutionalization in acutely ill hospitalized older patients. Pharmacol Res Perspect. 2017;5: e00310.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Egberts A, Moreno-Gonzalez R, Alan H, et al. Anticholinergic drug burden and delirium: a systematic review. J Am Med Dir Assoc. 2021;22:65-73.e4.

    Article  PubMed  Google Scholar 

  16. Greenblatt DJ, Miller LG, Shader RI. Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. Am J Med. 1990;88:18S-24S.

    Article  CAS  PubMed  Google Scholar 

  17. Araklitis G, Robinson D, Cardozo L. Cognitive effects of anticholinergic load in women with overactive bladder. Clin Interv Aging. 2020;15:1493–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kuhr BM. Prolonged delirium with propanolol. J Clin Psychiatry. 1979;40:198–9.

    CAS  PubMed  Google Scholar 

  19. Arber N. Delirium induced by atenolol. BMJ. 1988;297:1048.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Fisher AA, Davis M, Jeffery I. Acute delirium induced by metoprolol. Cardiovasc Drugs Ther. 2002;16:161–5.

    Article  PubMed  Google Scholar 

  21. Kogoj A. Suspected propranolol-induced delirium. Can J Psychiatry. 2004;49:645.

    Article  PubMed  Google Scholar 

  22. Wasik KK, Michaels AD. Acute delirium induced by carvedilol: a case report. J Med Cases. 2013;4:732–3.

    Google Scholar 

  23. Aikoye SA, Jafferany M, Osuagwu V, et al. The man who saw things on carvedilol. Tokai J Exp Clin Med. 2019;44:29–30.

    PubMed  Google Scholar 

  24. Duan Y, Grady JJ, Albertsen PC, et al. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018;27:340–8.

    Article  CAS  PubMed  Google Scholar 

  25. Franco-Salinas G, de la Rosette JJMCH, Michel MC. Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet. 2010;49:177–88.

    Article  CAS  PubMed  Google Scholar 

  26. Okura T, Yamada S, Abe Y, et al. Selective and sustained occupancy of prostatic alpha1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats. J Pharm Pharmacol. 2002;54:975–82.

    Article  CAS  PubMed  Google Scholar 

  27. Matsuoka H, Yoshiuchi K, Koyama A, et al. Chemotherapeutic drugs that penetrate the blood-brain barrier affect the development of hyperactive delirium in cancer patients. Palliat Support Care. 2015;13:859–64.

    Article  PubMed  Google Scholar 

  28. Tsumura H, Satoh T, Ishiyama H, et al. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys. 2011;81:e385–92.

    Article  CAS  PubMed  Google Scholar 

  29. Araki K, Naya Y, Inahara M, et al. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Int J Urol. 2014;21:815–9.

    Article  CAS  PubMed  Google Scholar 

  30. Takeda M, Yokoyama O, Yoshida M, et al. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study. Int J Urol. 2017;24:539–47.

    Article  CAS  PubMed  Google Scholar 

  31. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651–8.

    Article  PubMed  Google Scholar 

  32. Yoshida M, Kato D, Nishimura T, et al. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients. Int J Urol. 2018;25:855–62.

    Article  CAS  PubMed  Google Scholar 

  33. Leighton SP, Herron JW, Jackson E, et al. Delirium and the risk of developing dementia: a cohort study of 12 949 patients. J Neurol Neurosurg Psychiatry. 2022;93:822–7.

    Article  PubMed  Google Scholar 

  34. Kikkawa N, Sogawa R, Monji A, et al. Delirium risk of histamine-2 receptor antagonists and proton pump inhibitors: A study based on the adverse drug event reporting database in Japan. Gen Hosp Psychiatry. 2021;72:88–91.

    Article  PubMed  Google Scholar 

  35. Kotake K, Mitsuboshi S, Omori Y, et al. Evaluation of Risk of Cardiac or Cerebrovascular Events in Romosozumab Users Focusing on Comorbidities: Analysis of the Japanese Adverse Drug Event Report Database. J Pharm Technol. 2023;39:23–8.

    Article  CAS  PubMed  Google Scholar 

  36. Norwood PK, Sampson AR. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Stat Med. 1988;7:1023–30.

    Article  CAS  PubMed  Google Scholar 

  37. Praus M, Schindel F, Fescharek R, et al. Alert systems for post-marketing surveillance of adverse drug reactions. Stat Med. 1993;12:2383–93.

    Article  CAS  PubMed  Google Scholar 

  38. Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4:1112–5.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Abrams P, Amarenco G, Bakke A, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol. 2003;170:1242–51.

    Article  PubMed  Google Scholar 

  40. Griwan MS, Singh SK, Paul H, et al. The efficacy of tamsulosin in lower ureteral calculi. Urol Ann. 2010;2:63–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Hieble JP, Bylund DB, Clarke DE, et al. International union of pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev. 1995;47:267–70.

    CAS  PubMed  Google Scholar 

  42. Kojima Y, Sasaki S, Shinoura H, et al. Quantification of alpha1-adrenoceptor subtypes by real-time RT-PCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. Prostate. 2006;66:761–7.

    Article  CAS  PubMed  Google Scholar 

  43. Keating GM. Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs. 2015;75:207–17.

    Article  CAS  PubMed  Google Scholar 

  44. Takei R, Ikegaki I, Shibata K, et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999;79:447–54.

    Article  CAS  PubMed  Google Scholar 

  45. Fusco F, Palmieri A, Ficarra V, et al. α1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69:1091–101.

    Article  CAS  PubMed  Google Scholar 

  46. Shim SR, Kim JH, Chang IH, et al. Is tamsulosin 0.2 mg effective and safe as a first-line treatment compared with other alpha blockers? A meta-analysis and a moderator focused study. Yonsei Med J. 2016;57:407–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kim YJ, Tae BS, Bae JH. Cognitive function and urologic medications for lower urinary tract symptoms. Int Neurourol J. 2020;24:231–40.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Ulrich S. Differential prescription behavior in benign prostatic syndrome may explain relationship found between tamsulosin and dementia. Pharmacoepidemiol Drug Saf. 2018;27:1157–8.

    Article  PubMed  Google Scholar 

  49. Tae BS, Jeon BJ, Choi H, et al. α-Blocker and risk of dementia in patients with benign prostatic hyperplasia: a nationwide population based study using the national health insurance service database. J Urol. 2019;202:362–8.

    Article  PubMed  Google Scholar 

  50. Takeda M, Nishizawa O, Gotoh M, et al. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study. Urology. 2013;82:887–93.

    Article  PubMed  Google Scholar 

  51. Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol. 2009;56:534–41.

    Article  CAS  PubMed  Google Scholar 

  52. Yasuda K, Yamanishi T, Tojo M, et al. Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies. Prostate. 1994;25:46–52.

    Article  CAS  PubMed  Google Scholar 

  53. Nishino Y, Masue T, Miwa K, et al. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int. 2006;97:747–51.

    Article  CAS  PubMed  Google Scholar 

  54. Takahashi S, Tajima A, Matsushima H, et al. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol. 2006;13:15–20.

    Article  CAS  PubMed  Google Scholar 

  55. Yokoyama T, Uematsu K, Watanabe T, et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol. 2009;43:307–14.

    Article  CAS  PubMed  Google Scholar 

  56. Wagg A, Nitti VW, Kelleher C, et al. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016;32:621–38.

    Article  CAS  PubMed  Google Scholar 

  57. Welk B, Etaby K, McArthur E, et al. The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications. Neurourol Urodyn. 2022;41:348–56.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No specific funding was received.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Okayama Saiseikai General Hospital, 2-25 Kokutaicho, Kita-ku, Okayama-shi, Okayama, 700-8511, Japan

    Kazumasa Kotake, Yumi Noritake & Yasuhiro Kawakami

Authors
  1. Kazumasa Kotake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yumi Noritake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiro Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazumasa Kotake.

Ethics declarations

Conflicts of interests

The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file 1 (DOCX 17 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kotake, K., Noritake, Y. & Kawakami, Y. Association of silodosin, tamsulosin, and naftopidil with delirium: analysis of the pharmacovigilance database in Japan. Int J Clin Pharm 45, 1252–1259 (2023). https://doi.org/10.1007/s11096-023-01639-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-023-01639-0

Keywords

Search

Navigation